retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Retatrutide (40mg) First Retatrutide phase 3 data,

More recent research continues to suggest that there may be a signal worth paying attention to

BMI, body mass index

doi: 10.1111/j.1365-2125.2007.02890.x [DOI] [PMC free article] [PubMed] [Google Scholar] 74

doi: 10.1097/ALN.0000000000004776 [DOI] [PubMed] [Google Scholar] 184.Jensterle M, Ferjan S, Leai L, et al

In the safety profile, pooling three studies with 640 patients, most adverse events associated with retatrutide were mild and did not result in treatment discontinuation

It aids digestive regularity, which is crucial given the slowed gastric emptying caused by the medication, helping to manage both constipation and potentially diarrhea (depending on the type of fiber and hydration levels)